Plexium is a technology-enabled drug development company utilizing the latest advances in synthetic chemistry, assay modalities and microfluidics to unlock first-in-class therapeutics. Plexium focuses on extremely high-throughput empirical probing of protein-protein interactions in cell-based assays, utilizing DNA-encoded libraries. Utilizing this platform to manipulate E3 ligase interactions, and targeted protein degradation, brings a vast array of heretofore inaccessible biology under small-molecule control.